Synergy CHC Corp. (Uplisting) (SNYR) Competitors $5.82 -0.08 (-1.36%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends SNYR vs. INZY, KYTX, CRBU, ACTU, DMAC, NKTX, TNYA, SCPH, ADAP, and LFVNShould you be buying Synergy CHC Corp. (Uplisting) stock or one of its competitors? The main competitors of Synergy CHC Corp. (Uplisting) include Inozyme Pharma (INZY), Kyverna Therapeutics (KYTX), Caribou Biosciences (CRBU), Actuate Therapeutics (ACTU), DiaMedica Therapeutics (DMAC), Nkarta (NKTX), Tenaya Therapeutics (TNYA), scPharmaceuticals (SCPH), Adaptimmune Therapeutics (ADAP), and LifeVantage (LFVN). These companies are all part of the "pharmaceutical products" industry. Synergy CHC Corp. (Uplisting) vs. Inozyme Pharma Kyverna Therapeutics Caribou Biosciences Actuate Therapeutics DiaMedica Therapeutics Nkarta Tenaya Therapeutics scPharmaceuticals Adaptimmune Therapeutics LifeVantage Synergy CHC Corp. (Uplisting) (NASDAQ:SNYR) and Inozyme Pharma (NASDAQ:INZY) are both small-cap consumer staples companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends, valuation and community ranking. Which has stronger valuation & earnings, SNYR or INZY? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynergy CHC Corp. (Uplisting)N/AN/AN/AN/AN/AInozyme PharmaN/AN/A-$71.17M-$1.56-1.75 Do institutionals and insiders hold more shares of SNYR or INZY? 88.3% of Inozyme Pharma shares are owned by institutional investors. 11.2% of Inozyme Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media prefer SNYR or INZY? In the previous week, Inozyme Pharma had 2 more articles in the media than Synergy CHC Corp. (Uplisting). MarketBeat recorded 2 mentions for Inozyme Pharma and 0 mentions for Synergy CHC Corp. (Uplisting). Synergy CHC Corp. (Uplisting)'s average media sentiment score of 0.00 equaled Inozyme Pharma'saverage media sentiment score. Company Overall Sentiment Synergy CHC Corp. (Uplisting) Neutral Inozyme Pharma Neutral Is SNYR or INZY more profitable? Synergy CHC Corp. (Uplisting)'s return on equity of 0.00% beat Inozyme Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Synergy CHC Corp. (Uplisting)N/A N/A N/A Inozyme Pharma N/A -88.42%-57.02% Do analysts rate SNYR or INZY? Inozyme Pharma has a consensus target price of $15.71, indicating a potential upside of 475.61%. Given Inozyme Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Inozyme Pharma is more favorable than Synergy CHC Corp. (Uplisting).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synergy CHC Corp. (Uplisting) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Inozyme Pharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in SNYR or INZY? Inozyme Pharma received 50 more outperform votes than Synergy CHC Corp. (Uplisting) when rated by MarketBeat users. CompanyUnderperformOutperformSynergy CHC Corp. (Uplisting)N/AN/AInozyme PharmaOutperform Votes5086.21% Underperform Votes813.79% SummaryInozyme Pharma beats Synergy CHC Corp. (Uplisting) on 7 of the 9 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get Synergy CHC Corp. (Uplisting) News Delivered to You Automatically Sign up to receive the latest news and ratings for SNYR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNYR vs. The Competition Export to ExcelMetricSynergy CHC Corp. (Uplisting) IndustryStaples SectorNASDAQ ExchangeMarket Cap$44.57M$2.08B$14.91B$8.81BDividend YieldN/A15.15%2.68%4.06%P/E RatioN/A10.6923.9717.77Price / SalesN/A167.753.6575.18Price / CashN/A92.1119.1432.53Price / BookN/A1.485.894.68Net IncomeN/A$70.32M$581.83M$226.08M7 Day Performance-3.00%1.01%0.02%-1.04%1 Month PerformanceN/A0.74%-3.10%1.04%1 Year PerformanceN/A14.89%9.98%26.28% Synergy CHC Corp. (Uplisting) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNYRSynergy CHC Corp. (Uplisting)N/A$5.82-1.4%N/AN/A$43.94MN/A0.0040Gap UpINZYInozyme Pharma1.2361 of 5 stars$2.73-2.2%$15.71+475.6%-28.5%$175.38MN/A0.0050KYTXKyverna Therapeutics2.8357 of 5 stars$4.05-1.7%$25.71+534.9%N/A$174.84M$7.03M0.0096Analyst ForecastAnalyst RevisionGap UpCRBUCaribou Biosciences2.9415 of 5 stars$1.92-2.0%$11.25+485.9%-64.7%$173.86M$34.48M0.00100ACTUActuate TherapeuticsN/A$8.86+3.3%N/AN/A$173.04MN/A0.0010DMACDiaMedica Therapeutics1.902 of 5 stars$4.02-0.5%$7.00+74.1%+62.8%$171.90MN/A0.0020NKTXNkarta2.2027 of 5 stars$2.43-2.8%$16.50+579.0%-4.4%$171.49MN/A-1.33140TNYATenaya Therapeutics3.9769 of 5 stars$2.13-4.1%$14.75+592.5%+18.4%$168.74MN/A0.00110Gap UpSCPHscPharmaceuticals3.8122 of 5 stars$3.35-0.3%$15.00+347.8%-40.2%$167.63M$13.59M0.0030Analyst RevisionADAPAdaptimmune Therapeutics2.1006 of 5 stars$0.65-3.0%$3.16+390.3%+54.9%$165.04M$60.28M0.00449Analyst RevisionLFVNLifeVantage2.9406 of 5 stars$12.99+0.5%N/A+121.0%$162.64M$200.16M40.41260 Related Companies and Tools Related Companies Inozyme Pharma Competitors Kyverna Therapeutics Competitors Caribou Biosciences Competitors Actuate Therapeutics Competitors DiaMedica Therapeutics Competitors Nkarta Competitors Tenaya Therapeutics Competitors scPharmaceuticals Competitors Adaptimmune Therapeutics Competitors LifeVantage Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SNYR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synergy CHC Corp. (Uplisting) Please log in to your account or sign up in order to add this asset to your watchlist. Share Synergy CHC Corp. (Uplisting) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
